Argus analyst John Eade kept his Hold rating on Baxter after the company's Q1 earnings beat and raised FY18 outlook, saying he would consider an upgrade if the stock price pulled back to the mid-$60's range. The analyst notes that Baxter has "substantially improved profitability in recent quarters" even as it continues to rely on M&A as a source of revenue and margin growth. Eade adds that while the company's Renal and Hospital Products segments are mature businesses, the company's balance sheet is clean, and the management's recent dividend raise is indicative of its confidence in Baxter's prospects.